Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

12/20/2012 | 09:17am US/Eastern
   By Tess Stynes 
 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at Tess.Stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Merck & Co., Inc.
React to this article
Latest news on MERCK & CO., INC.
07/29 MERCK : New Human Papillomavirus Study Findings Have Been Reported by Investigat..
07/29 MERCK : Announces European Medicines Agency Acceptance of Marketing Authorizatio..
07/29 MERCK : Market commentary: Equities rebound while Ford Motors, Gilead Science's ..
07/29 MERCK : Equities rebound while Ford Motors and Gilead Science's results beat exp..
07/28DJGilead Sales Soar on Hepatitis Drugs
07/28 MERCK : & CO., INC. : Change in Directors or Principal Officers, Amendments to A..
07/28 MERCK : Pamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board of Direct..
07/28DJMerck Earnings Hurt by Arthritis Drug Knockoffs
07/28DJMERCK : Reports Better-Than-Seen Profits, Buy Of Cancer Drug Maker--Update
07/28DJMerck Earnings Hurt by Arthritis Drug Knockoffs
Advertisement
Chart
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
More Financials